Company Analysis Moderna
1. Summary
Advantages
- Price (27.35 $) is less than fair price (72.62 $)
- Current debt level 5.02% is below 100% and has decreased over 5 years from 8.33%.
Disadvantages
- Dividends (0%) are below the sector average (0.5261%).
- The stock's return over the last year (-65.37%) is lower than the sector average (-21.58%).
- The company's current efficiency (ROE=-28.77%) is lower than the sector average (ROE=14.17%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Moderna | Healthcare | Index | |
|---|---|---|---|
| 7 days | -0.4% | -21.2% | -0.3% |
| 90 days | 2.5% | -21.7% | 10% |
| 1 year | -65.4% | -21.6% | 9.7% |
MRNA vs Sector: Moderna has significantly underperformed the "Healthcare" sector by -43.79% over the past year.
MRNA vs Market: Moderna has significantly underperformed the market by -75.1% over the past year.
Stable price: MRNA is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: MRNA with weekly volatility of -1.26% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (27.35 $) is lower than the fair price (72.62 $).
Price significantly below the fair price: The current price (27.35 $) is 165.5% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (8.96) is lower than that of the sector as a whole (63.23).
P/E vs Market: The company's P/E (8.96) is lower than that of the market as a whole (89.86).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.39) is lower than that of the sector as a whole (18.83).
P/BV vs Market: The company's P/BV (1.39) is lower than that of the market as a whole (9.35).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (4.67) is lower than that of the sector as a whole (32.67).
P/S vs Market: The company's P/S indicator (4.67) is lower than that of the market as a whole (10.1).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-4.1) is lower than that of the sector as a whole (274.42).
EV/Ebitda vs Market: The company's EV/Ebitda (-4.1) is lower than that of the market as a whole (50.71).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 75.33% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (75.33%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-15.75%).
5.4. ROE
ROE vs Sector: The company's ROE (-28.77%) is lower than that of the sector as a whole (14.17%).
ROE vs Market: The company's ROE (-28.77%) is lower than that of the market as a whole (11.64%).
5.5. ROA
ROA vs Sector: The company's ROA (-21.87%) is lower than that of the sector as a whole (1.18%).
ROA vs Market: The company's ROA (-21.87%) is lower than that of the market as a whole (6.88%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (131.22%) is higher than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (131.22%) is higher than that of the market as a whole (11%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5261%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
